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H I G H L I G H T S
• Plasma PCSK9 level was increased in patients with poor/suboptimal glucoregulation.• Patients with poor glucoregulation had the highest levels of small, dense LDL (sdLDL) .• High PCSK9 correlated with small HDL particles in poor/suboptimal controlled type 1 diabetes mellitus (T1DM).• In well-controlled T1DM, PCSK9 level was inversely associated with sdLDL particles.• Metabolic control modifies association of PCSK9 and lipoprotein subclasses in T1DM.









A B S T R A C T
Background and aims: Dyslipidemia in type 1 diabetes mellitus (T1DM) is characterised by altered distributions
of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses. Recent studies suggested that
proprotein convertase subtilisin/kexin 9 (PCSK9) may contribute to the development of dyslipidemia in T1DM.
In this cross-sectional study, we investigated the association between PCSK9 and lipoprotein subclasses in young
T1DM patients, with respect to glycemic control.
Methods: Plasma PCSK9 and lipoprotein subclasses were determined in 207 patients with T1DM (106 boys and
101 girls), aged 13.9 ± 3.0 years and treated by intensive insulin therapy.
Results: Plasma PCSK9 levels significantly increased with worsening of glycemic control (p < 0.001). T1DM
patients with poor glucoregulation had the highest proportion of small, dense LDL (sdLDL) and smaller HDL
particles, as well. PCSK9 was positively associated with markers of glucose homeostasis and serum lipid para-
meters only in patients with suboptimal/poor glucoregulation. In well-controlled T1DM, plasma PCSK9 level was
inversely associated with a relative proportion of sdLDL particles (p < 0.01) and this association remained
significant in multivariate analysis. In T1DM patients with suboptimal/poor glycemic control, PCSK9 was po-
sitively associated with the proportion of the smallest HDL3c particles (p < 0.001), but negatively with HDL
size (p < 0.05).
Conclusions: The extent of achieved metabolic control modifies the association between PCSK9 and lipoprotein
subclasses in T1DM. Further investigations are needed to reveal whether the observed effects of glycemic control
on PCSK9 and sdLDL levels have causal consequences on CVD risk in young patients with T1DM.
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1. Introduction
The worsening of metabolic control in T1DM may trigger secondary
disorders of lipid metabolism [1]. In patients with poor and suboptimal
glucoregulation, the level of glycated hemoglobin (HbA1c) was found to
be positively associated with triglycerides (TG), low-density lipoprotein
(LDL) and non-high-density lipoprotein cholesterol (non-HDL-C) levels
[1]. Yet, T1DM patients with well-controlled glycemia tend to have
lipid levels within recommended values, or even may have increased
HDL-C, particularly, if they were treated by intensive insulin therapy
[2,3]. Dyslipidemia in T1DM is also characterised by qualitative
changes of plasma lipoproteins, the most prominent being alterations of
LDL particles [2].
In recent years, novel biomarkers for evaluation of dyslipidemia
have been identified, with potential for therapeutic targeting [4]. Pro-
protein convertase subtilisin/kexin 9 (PCSK9) is a serin-protease that
plays a pivotal role in LDL metabolism. PCSK9 binds to LDL receptors
(LDL-R) and promotes their intracellular degradation, resulting in in-
creased plasma LDL-C levels [4]. In addition to the previously observed
relationship with serum lipid parameters, PCSK9 also positively corre-
lates with markers of glucose homeostasis [5]. Similar results have also
been found in a large study carried out in healthy children and ado-
lescents [6]. Results of recent studies in patients with metabolic syn-
drome and type 2 diabetes suggested that PCSK9 might be one of the
factors responsible for the development of diabetic dyslipidemia and
increased CVD risk [7]. More recently, a first report has been published
on increased PCSK9 in patients with T1DM [8].
So far, a link between PCSK9 and sdLDL particles has been scarcely
investigated. A positive correlation was reported in patients with CVD
[9,10], whereas no association was found in healthy subjects [11,12].
Hence, it is possible that the relationship between circulating PCSK9
and sdLDL particles varies in health and diseases. Despite the growing
body of knowledge on the link between PCSK9 and plasma lipoproteins,
such association in pediatric patients with T1DM has not been explored
and identified so far. We hypothesized that the link between PCSK9 and
lipoprotein subclasses distributions in T1DM depends on the achieved
metabolic control, which could be related to insulin action/resistance
and plasma TG levels. Therefore, the aim of the present study was to
investigate the effect of glycemic control on the association between
PCSK9 and LDL and HDL subclasses in young T1DM patients.
2. Materials and methods
2.1. Study group
This cross-sectional study included 207 patients with T1DM, aged
13.9 ± 3.0 years (106 boys and 101 girls), recruited at the Mother and
Child Health Care Institute of Serbia “Dr Vukan Čupić" in Belgrade. The
diagnosis of T1DM was established following national and international
guidelines [13,14]. Mean duration of diabetes in the studied group was
6.5 years (median: 7 years; interquartile range: 4–8 years). The patients
were treated by intensive insulin regimen (mostly basal-bolus regimen)
in the form of multiple daily insulin injections (n=193) or by con-
tinuous subcutaneous insulin infusion, i.e. insulin pump (n=14). None
of the patients received lipid-lowering therapy. In all subjects, detailed
clinical examination and laboratory evaluation were performed,
showing no evidence of any diabetic complications. Patient's height,
weight, waist and hip circumferences were measured and pubertal
development stage was assessed (Tanner method). Body mass index
(BMI) was calculated and converted to z-score for the assessment of
nourishment status (z-scores between the 5th and 85th percentile were
criteria for normal weight, the scores ≥85th, but< 95th for
overweight and ≥95th percentile for obesity). Written, informed con-
sent was obtained from all children and their parents or guardians.
Study protocol was approved by the Ethics Committee of the Mother
and Child Health Care Institute of Serbia „ Dr Vukan Čupić” and con-
ducted in accordance with the Declaration of Helsinki.
2.2. Laboratory analyses
Blood samples were obtained after an overnight fast. Serum levels of
glucose, total cholesterol (TC), HDL-C and TG were determined by
standard enzymatic methods. The level of LDL-C was calculated by the
Friedwald equation. A competitive turbidimetric inhibition im-
munoassay was used for HbA1c determination and estimated average
glucose (eAG) level was also calculated. All assays were performed
using Roche/Hitachi c501 automated analyser (Roche, Mannheim,
Germany). Achieved glycemic control was assessed based on HbA1c
levels, as follows: HbA1c< 7.5% was a criterion for good glycemic
control, the level of HbA1c≥ 7.5%, but< 9% for suboptimal and the
level ≥9% was an indicator of poor glycemic control [15]. Urinary
albumin concentration was measured by immunonefelometric method
in the timed overnight sample with Siemens nefelometer BN ProSpec®
System (Siemens, Erlangen, Germany). Early elevation of albumin ex-
cretion rate was considered as ≥ 7.5 μg/min [16]. Insulin resistance in
T1DM patients was assessed by estimated glucose disposal rate (eGDR)
[17]. The lower eGDR level is an indicator of greater insulin resistance
[17].
Concentration of PCSK9 was measured in plasma by quantitative
sandwich enzyme immunoassay (Quantikine ELISA, R&D Systems
Europe Ltd). Plasma LDL and HDL particles were separated by gradient
gel electrophoresis method in Hoefer SE 600 Ruby electrophoresis unit
(Amersham Pharmacia Biotech, Vienna, Austria), as previously de-
scribed [18]. The gels were analysed by Image Scanner (Amersham
Pharmacia Biotech, Vienna, Austria) using the Image Quant software
(version 5.2; 1999; Molecular Dynamics, Sunnyvale, CA, USA). Dia-
meters of the most prominent peaks in the LDL and HDL regions were
calculated from the calibration curve and designed as LDL and HDL
sizes. The relative proportions of four LDL and five HDL subclasses were
determined by estimating the areas under the peaks of densitometric
scans corresponding to particular subclass. The proportion of sdLDL
particles was determined as the area of the densitometric scan at or
below 25.5 nm [19].
2.3. Statistical analysis
Normally distributed continuous variables were presented as
mean ± standard deviation and compared by ANOVA with the Tukey's
post hoc test or Student-t test. Skewed variables were presented as
median (interquartile range) and compared by Kruskal-Wallis test or
Mann-Whitney U test. All significant differences were further adjusted
for daily insulin dose and nourishment status (0-normal weight; 1-
overweight and obese), using parametric and non-parametric ANCOVA
tests. Categorical variables were presented as relative or absolute fre-
quencies and analysed by Chi-square tests for contingency tables.
Associations between PCSK9 levels and investigated clinical and la-
boratory variables were assessed by Pearson's correlation analysis.
Multiple linear regression analysis was used to seek possible in-
dependent association between PCSK9, lipoprotein subclasses, clinical
and laboratory variables. Lipoprotein subclasses data and laboratory
variables which correlated with PCSK9 in univariate analysis were in-
cluded in the models for multiple testing. Lipoprotein particle sizes and
subclasses proportions were put in the separate models and adjusted for
gender, nourishment status and other variables whose p values in
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univariate analysis were ≤0.1. All variables were entered in the models
as continuous, except gender and nourishment status. Differences with
p < 0.05 were considered as statistically significant.
3. Results
3.1. Clinical and laboratory variables according to glycemic control
Demographic and clinical data of T1DM patients with respect to
glycemic control are shown in Table 1. The groups of good, suboptimal
and poor glucoregulation had similar age and gender distribution and
showed no difference in diabetes duration. Also, we found no sig-
nificant differences in anthropometric variables between groups. The
patients with suboptimal and poor glycemic control received a higher
dose of insulin per day.
Serum lipid and lipoprotein subclasses profile of T1DM patients are
presented in Table 2. The groups of suboptimal and poor glucoregula-
tion had significantly higher TC, TG and LDL-C levels than the patients
with good glycemic control. The level of HDL-C did not differ between
groups. The differences in TC, LDL-C and TG levels remained significant
after adjustment for daily insulin dose (p < 0.01 for each comparison)
and after adjustment for nourishment status (p < 0.01 for each com-
parison). Analysis of LDL subclasses revealed a gradual rearrangement
toward smaller particles with deterioration of glycemic control, as
evidenced by a significant reduction of LDL I (p < 0.05). In addition,
T1DM patients with poor glycemic control had the smallest HDL par-
ticle size, significantly less HDL2b, but more HDL 3c particles than the
groups with good and suboptimal glucoregulation. Group differences in
HDL size (p < 0.01) and relative proportions of LDL I, HDL 2b and HDL
3c subclasses persisted after adjustment for nourishment status
(p < 0.01, p < 0.05 and p < 0.01, respectively), as well as after ad-
justment for daily insulin dose (p < 0.05 for each comparison).
3.2. PCSK9 levels according to glycemic control
No difference in PCSK9 levels was found between boys (median:
210.81 ng/mL; interquartile range: 182.81–259.00 ng/mL) and girls
(median: 235.56 ng/mL; interquartile range: 188.61–277.22 ng/mL;
p=0.226). Next, we analysed gender-related differences in metabolic
syndrome traits and PCSK9 levels with respect to glycemic control. The
level of TG gradually increased with worsening of glycemic control in
both genders. In addition, boys with poor glucoregulation had sig-
nificantly higher level of glucose than boys with good glucoregulation.
We found no differences in metabolic syndrome traits and PCSK9 levels
between boys and girls with the same degree of glycemic control
(Supplementary Table 1).
Fig. 1 presents circulating PCSK9 levels in T1DM patients with re-
spect to glycemic control. We found that the level of PCSK9 sig-
nificantly increase as glycemic control worsens. In detail, PCSK9 level
in the group with good glucoregulation (median: 206.13 ng/mL; in-
terquartile range: 170.35–244.75 ng/mL) was significantly lower than
the level in T1DM patients with suboptimal (median: 221.78 ng/mL;
interquartile range: 193.00–264.57 ng/mL) and poor glucoregulation
(median: 293.00 ng/mL; interquartile range: 237.74–338.43 ng/mL).
The difference in PCSK9 levels between the groups with suboptimal and
poor glycemic control was also significant (p < 0.001). Group
Table 1
Demographic and clinical data of T1DM patients according to glycemic control.








Age (years) 14.1 ± 3.4 13.9 ± 2.7 13.8 ± 3.0 0.818
Gender (boys/girls), % 51.7/48.3 51.8/48.2 48.6/51.4 0.943
Pubertal status, % 0.469
Prepubertal 20.7 21.7 18.9
Pubertal 23.0 33.7 35.1
Postpubertal 56.3 44.6 45.9
Diabetes duration (years)a 6.0 (4.0–8.0) 7.0 (5.0–8.0) 7.0 (4.0–9.0) 0.345
Age at diabetes onset (years)a 8.0 (5.0–11.0) 6.0 (4.0–11.0) 6.5 (4.0–9.0) 0.288
BMI (kg/m2) 20.1 ± 3.3 20.2 ± 3.2 20.8 ± 3.7 0.564
BMI z-scorea 0.25 (−0.38–0.68) 0.30 (−0.40–0.80) 0.40 (−0.58–1.08) 0.517
Nourishment status, % 0.100
Normal weight 88.4 86.7 70.3
Overweight 8.1 10.8 21.6
Obese 3.5 2.4 8.1
Waist circumference (cm) 73.8 ± 9.0 73.8 ± 8.6 75.4 ± 8.4 0.642
Hip circumference (cm) 91.4 ± 12.3 91.5 ± 10.8 93.3 ± 9.9 0.746
Insulin dose (U/kg/day)a 0.97 (0.71–1.14) 1.05 (0.89–1.24) bb 1.07 (0.89–1.31)b <0.01
Glucose (mmol/L) 10.32 ± 4.24 11.86 ± 4.41 12.79 ± 5.54 b <0.05
HbA1c (%) 6.8 ± 0.5 8.1 ± 0.4 bb 10.4 ± 1.9 bb, cc < 0.001
eAG (mmol/L) 8.21 ± 0.90 11.00 ± 5.96 bb 14.07 ± 3.32 bb, cc < 0.001
Urinary albumin excretion rate (μg/min)a 4.3 (2.9–6.8) 4.4 (2.6–7.5) 5.2 (3.2–8.0) 0.848
Elevated albumin excretion rate, % 22.5 25.0 32.1 0.611
HbA1c: glycated hemoglobin; BMI: body mass index; eAG: estimated average glucose.
a Data are compared by Kruskal-Wallis test and presented as median (interquartile range).
b Significantly different from group with good glucoregulation (b: p < 0.05; bb: p < 0.01).
c Significantly different from group with suboptimal glucoregulation (c: p < 0.05; cc: p < 0.01).
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differences remained significant after adjustment for daily insulin dose
(p < 0.001) and nourishment status (p < 0.001). Similar trends were
found for the effect of glucoregulation when boys and girls were ana-
lysed separately (Supplementary Table 1).
3.3. Correlations of PCSK9 with lipoprotein subclasses
Univariate and multivariate associations of circulating PCSK9 levels
with lipoprotein subclasses and clinical and laboratory variables, with
respect to the achieved glycemic control, are shown in Table 3. Simple
regression analysis in the subgroup with good glucoregulation showed
that PCSK9 correlated positively with LDL size, but negatively with
relative proportion of sdLDL particles, while the association with HDL
size and the levels of HbA1c and TG did not reach statistical
significance. In patients with suboptimal/poor glycemic control, con-
centration of PCSK9 was positively associated with daily insulin dose,
HbA1c, TC, LDL-C and TG concentrations. In this group of T1DM pa-
tients PCSK9 levels were inversely associated with HDL size and posi-
tively with proportions of HDL 3c subclasses. To further explore the
relationship between PCSK9 and lipoprotein subclasses characteristics,
two linear regression models were generated. In T1DM patients with
good glucoregulation, the following variables were included in the
model 1: LDL size, gender, nourishment status, HDL size, HbA1c and TG
levels. In model 2, the proportion of sdLDL particles was entered in-
stead of LDL size, while other variables were same as in the model 1.
Following multivariate analysis, PCSK9 remained significantly asso-
ciated with LDL size (β= 0.303; p < 0.01; model 1), as well as with
the relative proportion of sdLDL particles (β=−0.304; p < 0.01;
model 2). In T1DM patients with suboptimal/poor glucoregulation,
model 1 included HDL size, gender, nourishment status, insulin dose,
HbA1c, TC, LDL-C and TG levels. In model 2, the proportion of HDL 3c
particles was included instead of HDL size. In multivariate analysis, the
association between PCSK9 and proportion of HDL 3c particles re-
mained significant (β=0.245; p < 0.01; model 2), while the asso-
ciation between PCSK9 and HDL size was lost (β=−0.002; p=0.983;
model 1).
3.4. Correlations of PCSK9 and sdLDL with eGDR, an index of insulin
resistance in T1DM
A correlation of PCSK9 level and sdLDL proportion with eGDR, an
index of insulin resistance in T1DM, was also analysed. In T1DM pa-
tients with good glucoregulation, we found an inverse association be-
tween eGDR and PCSK9 levels (β=−0.233; p < 0.05), while the as-
sociation between eGDR and proportion sdLDL particles was not
significant (β=0.184; p=0.111). Similarly, in T1DM patients with
suboptimal/poor glucoregulation, eGDR showed a negative correlation
with the levels of PCSK9 (β=−0.276; p < 0.01) and no association
with sdLDL proportions (β=−0.089; p=0.378). Finally, we found an
Table 2
Lipid profile of T1DM patients according to glycaemic control.
Parameter Glucoregulation p value
Good Suboptimal Poor
HbA1c < 7.5% (n=87) 7.5%≤HbA1c < 9% (n=83) HbA1c≥ 9% (n=37)
TC (mmol/L) 3.89 ± 0.60 4.25 ± 0.88 b 4.94 ± 1.15 bb, cc < 0.001
TG (mmol/L)a 0.61 (0.52–0.78) 0.79 (0.65–0.93) bb 0.93 (0.66–1.32) bb,c < 0.001
LDL-C (mmol/L) 1.94 ± 0.55 2.20 ± 0.75 b 2.77 ± 1.02 bb, cc < 0.001
HDL-C (mmol/L) 1.65 ± 0.36 1.66 ± 0.36 1.59 ± 0.49 0.639
LDL size (nm) 26.29 ± 1.17 26.43 ± 1.30 25.95 ± 1.25 0.147
LDL size≤ 25.5 nm, % 25.0 27.7 37.8 0.347
LDL I (%) 22.4 ± 5.8 24.9 ± 8.2 20.5 ± 7.4c∗ <0.05
LDL II (%) 27.2 ± 5.2 27.6 ± 5.2 28.5 ± 7.6 0.527
LDL III (%) 21.3 ± 3.7 20.6 ± 4.5 22.2 ± 6.2 0.227
LDL IV (%) 29.2 ± 5.8 26.8 ± 6.4 28.8 ± 12.2 0.122
sdLDL (%) 50.4 ± 8.0 47.5 ± 9.3 51.0 ± 11.8 0.063
HDL size (nm) 10.17 ± 0.79 10.06 ± 0.92 9.35 ± 1.00 bb, cc < 0.001
HDL size≤ 8.8 nm, % 11.9 20.5 45.9 <0.001
HDL 2b (%) 42.9 ± 8.8 41.9 ± 7.5 38.0 ± 7.4 bb,c < 0.01
HDL 2a (%) 21.5 ± 4.4 20.4 ± 3.0 21.1 ± 3.8 0.164
HDL 3a (%) 16.8 ± 3.6 17.6 ± 5.0 18.2 ± 5.4 0.239
HDL 3b (%) 10.4 ± 4.5 11.1 ± 5.2 11.4 ± 3.9 0.430
HDL 3c (%) 8.4 ± 4.4 8.9 ± 3.9 11.2 ± 4.3 bb,c < 0.01
HbA1c: glycated hemoglobin; TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; sdLDL:
small, dense low-density lipoprotein.
a Data are compared by Kruskal-Wallis test and presented as median (interquartile range).
b Significantly different from group with good glucoregulation (b: p < 0.05; bb: p < 0.01).
c Significantly different from group with suboptimal glucoregulation (c: p < 0.05; cc: p < 0.01).
Fig. 1. Circulating PCSK9 levels in T1DM patients according to glycemic con-
trol.
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inverse association between sdLDL proportion and insulin dose in
T1DM patients with good glucoregulation (β=−0.240; p < 0.05),
whereas insulin dose was not associated with the proportion of sdLDL
particles in the T1DM group with suboptimal/poor glucoregulation
(β=−0.065; p=0.493).
4. Discussion
In the present study, we investigated the association between cir-
culating PCSK9 levels and lipoprotein size heterogeneity in pediatric
patients with T1DM, who were treated with intensive insulin therapy
and were free of any diabetic complications. To the best of our
knowledge, this is the first investigation addressing the relationship
between PCSK9 and lipoprotein subclasses in pediatric population with
T1DM, with respect to achieved metabolic control.
The main finding of the current study is that the extent of achieved
metabolic control could modify associations between PCSK9 and lipo-
protein subclasses in T1DM. We found that pediatric T1DM patients
with poor glucoregulation had increased levels of both PCSK9 and
sdLDL particles, similarly as other high-risk populations and patients
with CVD [7–9]. The main reason for accumulation of sdLDL particles
in the plasma of T1DM patients with deteriorated glycemic control is
overproduction and/or delayed catabolism of TG-rich lipoproteins [3].
A positive association between PCSK9 and TG levels has been pre-
viously described [20] and it is also documented in the current study
(Table 3). It has been demonstrated that PCSK9 mediates synthesis of
apoB-100 and assembly of TG-rich lipoproteins [21], but also that it
may delay the uptake of TG-rich lipoproteins via LDL-R [11]. All of the
above-mentioned mechanisms promote hypertriglyceridemia and ac-
cumulation of sdLDL particles. Notably, PCSK9 promotes LDL-R de-
gradation [4] and sdLDL particles are cleared less efficiently via LDL-R
[22].
Adverse changes in HDL subclasses distribution, structure and
functionality have been well characterised in patients with diabetes
[3,23]. On the other hand, limited data regarding the link between
PCSK9 and HDL subclasses has been reported and no previous study
investigated this association in diabetes. Apparently, higher PCSK9 is
associated with smaller HDL subclasses in patients with CVD [24] and
PCSK9 inhibitor therapy predominantly increases large HDL particles
[25]. In the current study, higher PCSK9 levels were positively asso-
ciated with smaller HDL 3c subclasses in patients with suboptimal and
poor glycemic control (Table 3). This finding completes previously re-
ported data on distinguishing effects of glucoregulation on PCSK9-
mediated dyslipidemia in T1DM [26].
The most intriguing finding of the present study is the inverse as-
sociation of PCSK9 and sdLDL particles in patients with optimal gly-
cemic control. This association remained significant in a multivariate
analysis (Table 3). Available literature data indicate that plasma sdLDL
particles are positively related to the levels of PCSK9, at least in patients
with CVD [9,10]. The observed reciprocal association between PCSK9
and sdLDL in our study could be assigned to the effects of insulin ad-
ministration, since insulin increases PCSK9, but lowers sdLDL [27]. In
line with previous, insulin dose was inversely associated with the pro-
portion of sdLDL in our patients with well-controlled T1DM. Another
possible explanation relies on the data from in vitro studies, which
provided evidence that a great portion of plasma PCSK9 is actually
bound to LDL particles [28]. It has been demonstrated that upon at-
tachment to LDL, PCSK9 has delayed plasma clearance and, more im-
portantly, loses its ability to mediate LDL-R degradation [29]. Our
findings fit the conclusion of Glerup and colleagues [30] that plasma
LDL-C level (or LDL particles number) may serve as a feedback me-
chanism that regulates PCSK9 activity. Conversely, there is also the
possibility that LDL-bound PCSK9 form has residual activity toward
LDL-R [31]. Namely, PCSK9 can be found in two main forms in plasma,
as an LDL-bound form and as a free, mature PCSK9 [31]. Based on the
findings that cleavage of free PCSK9 by plasma protease furin reduces
Table 3
Univariate and multivariate linear regression analyses of the association between PCSK9 level and lipoprotein subclasses in T1DM patients stratified by glucor-
egulation.
Patients with good glucoregulation (n= 87) Patients with suboptimal and poor glucoregulation (n= 120)
Variable β p value Variable β p value
Unadjusted LDL size (nm) 0.215 < 0.05 HDL size (nm) −0.184 <0.01
sdLDL (%) −0.312 <0.01 HDL 3c (%) 0.318 <0.001
HDL size (nm) −0.207 0.058 Insulin dose (U/kg/day) 0.200 <0.05
HbA1c (%) 0.202 0.062 HbA1c (%) 0.332 <0.001
TG (mmol/L) 0.197 0.069 TC (mmol/L) 0.321 <0.001
TG (mmol/L) 0.345 <0.001
LDL-C (mmol/L) 0.283 <0.01
Model 1a LDL size (nm) 0.303 < 0.01 HDL size (nm) −0.002 0.983
HbA1c (%) 0.199 0.068 Insulin dose (U/kg/day) 0.193 <0.05
TG (mmol/L) 0.112 0.318 HbA1c (%) 0.132 0.187
HDL size (nm) −0.301 <0.01 TC (mmol/L) 0.250 0.243
TG (mmol/L) 0.290 <0.001
LDL-C (mmol/L) −0.097 0.646
Model 2a sdLDL (%) −0.304 <0.01 HDL 3c (%) 0.245 <0.01
HbA1c (%) 0.171 0.116 Insulin dose (U/kg/day) 0.157 0.074
TG (mmol/L) 0.061 0.588 HbA1c (%) 0.133 0.164
HDL size (nm) −0.233 <0.01 TC (mmol/L) 0.338 0.080
TG (mmol/L) 0.219 <0.001
LDL-C (mmol/L) −0.194 0.311
LDL: low-density lipoprotein; sdLDL: small, dense low-density lipoprotein; HDL: high-density lipoprotein; HbA1c: glycated hemoglobin; TG: triglycerides; TC: total
cholesterol.
a Categorical variables included in Models 1 and 2: gender (0-girl; 1-boy) and nourishment status (0- normal weight; 1- overweight and obese).
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its activity, whereas PCSK9 bound to LDL remains intact, it is con-
sidered that LDL-bound form of PCSK9 has biological activity [32]. The
observed inconsistency between the results mainly originates from the
different methodology and experimental models. Whether measure-
ments of LDL-bound PCSK9 and/or PCSK9 activity might be a more
accurate marker of PCSK9 function and physiological effects remains to
be further established.
Expression of circulating PCSK9 is regulated by sterol response
binding element protein-2 (SREBP-2) and has marked diurnal rhythm,
parallel to cholesterol synthesis [33]. In addition, multiple genetic,
hormonal and metabolic factors may influence plasma PCSK9 level
[30]. Regulation of PCSK9 production is different in insulin deficiency
and insulin resistance state. Namely, experimental model of T1DM
demonstrated that insulin deficiency reduce hepatic PCSK9 gene ex-
pression [34]. Based on the data from in vitro studies, synthesis of
PCSK9 in hepatic cells increases in the presence of insulin [35,36]. On
the other hand, in the clinical setting of insulin resistance, acute hy-
perinsulinemia (induced by euglycemic clamp) significantly decreased
circulating PCSK9 levels. Therefore, a hypothesis has been raised that
plasma PCSK9 level is inversely related to hepatic insulin sensitivity in
the case of acute induced hyperinsulinemia [5]. In our study, higher
PCSK9 levels were associated with greater insulin resistance (as in-
dicated by lower eGDR), regardless of glycemic control. Greater insulin
resistance is associated with higher risk of micro- and macrovascular
complications in T1DM, including dyslipidemia [37]. These data in-
dicate that insulin resistance could be a link between PCSK9 and lipo-
protein subclasses distribution in T1DM, although underlying me-
chanisms behind these associations are yet to be established.
Intensive insulin therapy delays the onset and slows the progression
of complications in T1DM [15]. Data from the study involving parti-
cipants of the Diabetes Control and Complications Trial showed that the
patients treated by intensive insulin therapy had less sdLDL and smaller
HDL particles than those on conventional insulin regimen [27]. How-
ever, to the best of our knowledge, no clinical trial investigated effects
of intensive insulin treatment on PCSK9 levels so far. Having in mind
recent achievements on LDL reduction with novel PCSK9 inhibitor
therapy [38], further studies on PCSK9 in T1DM patients are warranted.
The cross-sectional design of our study allowed us to demonstrate
associations, while conclusions regarding causality cannot be drawn.
Future studies with isolated lipoprotein subclasses would be required to
give an insight into mechanisms behind the observed associations. Also,
data on disposition index would additionally support the potential role of
insulin resistance on PCSK9 level and qualitative changes in lipoprotein
distribution in T1DM. Since currently available ELISA tests are not able
to distinguish various forms of PCSK9, but measure its total plasma level,
development of the tests to quantify both PCSK9 forms and/or PCSK9
activity would enable further insight into role of PCSK9 in T1DM.
In conclusion, the results of our study show that association of
PCSK9 level with LDL and HDL subclasses in T1DM is influenced by the
extent of achieved metabolic control. In well-controlled T1DM, plasma
PCSK9 level was independently and inversely related to sdLDL parti-
cles, whereas such association was lost with worsening of glucor-
egulation. Further investigations are needed to reveal whether the ob-
served effects of glycemic control on PCSK9 and sdLDL levels have
causal consequences on CVD risk in young patients with T1DM.
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